Skip to content
Screener

EPS (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
$7.94+26.2%
Pfizer logo
PfizerPFE
-$0.04-108%
Merck & Co. logo
Merck & Co.MRK
-$0.54-131%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$4.31+8.0%
Cytokinetics logo
CytokineticsCYTK
-$1.50-33.9%
Mannkind logo
MannkindMNKD
-$0.06

Other financials

Income statement

See full
Revenue$692.0K-97.6%
Gross profit$653.0K-97.7%
Operating income-$26.5M-810%
Net income-$31.8M-1,077%

Balance sheet

See full
Cash & equivalents$40.9M-18.7%
Total debt$59.2M-3.6%
Total equity$174.5M+34.8%
Total assets$250.1M+10.9%

Cash flow

See full
Operating cash flow-$9.2M
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$1.05B+151%
Enterprise value$1.07B+149%
P/S25.3×+18.1×

Profitability

See full
Gross margin99.1%0.0pp
Operating margin-131.4%-34.2pp
Net margin-147.4%-32.8pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-40.2%-11.2pp
Debt / equity0.3×-0.1×
Current ratio13.4×+9.2×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001062822-26-000117
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss on early extinguishment of debt(4,349)(4,349)
Net (loss) income$(31,775)$3,252$(32,818)$(22,043)
Net (loss) income per common share, basic$(0.07)$0.01$(0.08)$(0.06)
Net (loss) income per common share, diluted$(0.07)$0.01$(0.08)$(0.06)
Weighted average common shares outstanding, basic437,653363,294419,050362,687
Weighted average common shares outstanding, diluted437,653363,570419,050362,687
Other comprehensive (loss) income:
Unrealized loss on investments(74)(39)(234)(133)

Item 1. Financial Statements

FAQ

What is Lexicon Pharmaceuticals's EPS (diluted)?
Lexicon Pharmaceuticals (LXRX) reported EPS (diluted) of -$0.07 in Q2 2026.
How has Lexicon Pharmaceuticals's EPS (diluted) changed year-over-year?
Lexicon Pharmaceuticals's EPS (diluted) decreased by 800.0% year-over-year, from $0.01 to -$0.07.
What is the long-term trend for Lexicon Pharmaceuticals's EPS (diluted)?
Over 2 years (2023 to 2025), Lexicon Pharmaceuticals's EPS (diluted) has grown at a -58.2% compound annual growth rate (CAGR), from -$0.80 to -$0.14.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Lexicon Pharmaceuticals's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude